Cerebral Microbleeds as Predictor of Future Intra-Cerebral Hemorrhage During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Edoxaban (Primary) ; Apixaban; Dabigatran etexilate; Rivaroxaban; Warfarin
- Indications Stroke
- Focus Therapeutic Use
- Acronyms CMB-NOW
- 18 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
- 08 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov record.